. 2015 Nov 17;19(13):2475–2483. doi: 10.1017/S1368980015003262

Table 3.

Baseline characteristics of the population stratified by chronic condition status in 2004/5; people from three Central Australian Aboriginal communities

	Diabetes (n 40; 14·0 %)		Hypertension (n 48; 16·8 %)		CVD (n 18; 6·3 %)		Chronic kidney disease (n 69; 24·1 %)
	Mean	95 % CI	Mean	95 % CI	Mean	95 % CI	Mean	95 % CI
Age (years)	31	27, 35	39^†	34, 43	42^†	35, 49	33	30, 37
Sex (% male)	32·5	18·0, 47·0	70·8^†	58·0, 83·6	61·1	38·6, 83·6	46·4	34·6, 58·1
Smoking (%)	35·0	20·2, 49·8	29·2	16·3, 42·0	27·8	7·1, 48·5	31·9	20·9, 42·9
Height (cm)	1·66	1·63, 1·68	1·68	1·66, 1·70	1·69	1·66, 1·72	1·67	1·65, 1·69
Weight (kg)	72·2^†	66·8, 77·7	73·1^†	68·9, 77·2	76·5^†	68·8, 84·1	67·0,	63·5, 70·6
BMI (kg/m²)	26·2^†	24·5, 27·9	25·9^†	24·5, 27·4	26·7^†	24·1, 29·3	24·0	22·8, 25·4
Sum of skinfolds (mm)	91·3^†	79·2, 103·5	84·3	72·8, 95·8	83·6	62·1, 105·2	75·7	65·3, 86·2
Waist-to-hip ratio	0·89^†	0·87, 0·92	0·89^†	0·87, 0·91	0·91^†	0·87, 0·95	0·86	0·85, 0·88
Cholesterol (mmol/l)^*	4·99	4·63, 5·37	5·16^†	4·88, 5·45	5·44	4·84, 6·12	4·85	4·59, 5·13
TAG (mmol/l)^*	1·65	1·41, 1·95	2·09^†	1·80, 2·42	2·51^†	1·98, 3·19	1·79	1·57, 2·05
Homocysteine (µmol/l)^*	12·1	10·8, 13·5	15·2^†	13·7, 16·8	16·2^†	13·5, 19·5	13·8	12·5, 15·3
Retinol (µg/dl)^*	41·2	37·0, 45·8	49·4^†	45·3, 53·8	49·0	41·4, 57·9	44·5	41·0, 48·3
α-Tocopherol (µg/dl)^*	708	634, 790	692	639, 750	775	669, 897	702	651, 7·57
Lutein + zeaxanthin (µg/dl)^*	7·38	6·59, 8·26	7·29	6·61, 8·04	7·30	5·74, 9·28	6·91	6·31, 7·57
Cryptoxanthin (µg/dl)^*	2·98	2·43, 3·66	2·70	2·28, 3·21	2·01^†	1·51, 2·68	2·64	2·28, 3·05
Lycopene (µg/dl)^*	11·23	9·35, 13·48	8·67	7·21, 10·44	6·93	4·99, 9·61	9·34	7·98, 10·94

Data are mean and 95 % CI unless otherwise indicated.

Geometric mean and 95 % CI.

^†

Difference between those with chronic condition and those without is statistically significant at the 95 % CI level.